Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8157792 | 0.90 | KLK5 (0.47) | KLK5TRPM8CTSBSPPL2ACTRB1 | |
| SCHEMBL9058446 | 0.88 | KLK5 (0.49) | KLK5TRPM8MMP8ATMCTSB | |
| SCHEMBL6654213 | 0.88 | TRPM8 (0.58) | KLK5TRPM8ATMCTSBSPPL2A | |
| SCHEMBL3023447 | 0.88 | TRPM8 (0.58) | KLK5TRPM8ATMCTSBSPPL2A | |
| SCHEMBL3023446 | 0.88 | TRPM8 (0.58) | KLK5TRPM8ATMCTSBSPPL2A | |
| SCHEMBL2577615 | 0.88 | TRPM8 (0.58) | KLK5TRPM8ATMCTSBSPPL2A | |
| SCHEMBL6500127 | 0.88 | TRPM8 (0.58) | KLK5TRPM8ATMCTSBSPPL2A | |
| SCHEMBL7492033 | 0.87 | KLK5 (0.51) | KLK5TRPM8 | |
| SCHEMBL7492515 | 0.87 | KLK5 (0.51) | KLK5TRPM8 | |
| SCHEMBL7462812 | 0.87 | KLK5 (0.51) | KLK5TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307184-B2 | Processes for preparing oxazolidinone derivatives of β-hydroxyethlamine compounds and for preparing β-hydroxyethlamine compounds | KANEKA CORPORATION (JP) | 2007-12-11 | — | — | US | disclosed |
| US-20040181074-A1 | Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound | KANEKA CORPORATION (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1403257-A1 | PROCESSES FOR PRODUCING OXAZOLIDINONE DERIVATIVE OF BETA-HYDROXYETHYLAMINE COMPOUND AND FOR PRODUCING BETA-HYDROXYETHYLAMINE COMPOUND | KANEKA CORPORATION (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181074-A1 | Process for producing oxazolidinone derivative of beta-hydroxyethylamine compound and for producing beta-hydroxyethlamine compound | HNMT, PNMT, HRH4 | KLK5 1847/4885TRPM8 3960/4885MMP8 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.